U.S., Feb. 15 -- ClinicalTrials.gov registry received information related to the study (NCT06826612) titled 'A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease' on Feb. 03.
Brief Summary: The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
Study Start Date: Feb. 28
Study Type: INTERVENTIONAL
Condition:
Huntington Disease
Intervention:
GENETIC: SPK-10001
Specified dose on specified days
OTHER: Placebo Surgery Control
Placebo Surgery procedure for SPK-10001
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Spark Therapeutics, Inc.
Published by HT Digital Content Services with permission from Health D...